RGNT
Regentis Biomaterials Ltd.
NYSE AmericanUSDEQUITY
Healthcare
DELAYED
Last price
2.15
▲ 0.09 (4.37%)
MARKET · —
Price
Open
2.15
Prev close
2.06
Day high
2.17
Day low
2.07
Volume
37.13K
Market cap
$14.75M
P/E (TTM)
—
52W range
1.23 – 15.50
Trailing performance
Returnvs SPY
1W
+5.00%
+6.4%
1M
+7.69%
+4.0%
3M
-2.33%
-5.4%
6M
-48.59%
-59.7%
YTD
-68.84%
-81.1%
1Y
—
-20.0%
3Y
—
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$14.75M
Enterprise value$4.70M
Revenue (TTM)—
Gross profit—
EBITDA—
Net income$-13.69M
EPS (TTM)$-24.16
Free cash flow$3.03M
Total cash$7.38M
Total debt$1.20M
Book value / share$0.92
Shares outstanding7.02M
Float2.42M
Short % of float0.73%
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book2.29
EV / revenue—
EV / EBITDA—
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets-107.53%
Debt / equity25.23
Current ratio2.65
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 |
|---|---|
| Total revenue | $0 |
| Cost of revenue | $0 |
| Gross profit | $0 |
| R&D | — |
| SG&A | — |
| Operating income | — |
| Pre-tax income | — |
| Tax provision | $0 |
| Net income | -$13.65M |
| EBIT | $0 |
| Line item | 2025 |
|---|---|
| Cash & equivalents | — |
| Short-term investments | — |
| Net receivables | — |
| Inventory | — |
| Total current assets | — |
| Total assets | — |
| Total current liabilities | — |
| Long-term debt | — |
| Total liabilities | — |
| Retained earnings | — |
| Shareholder equity | — |
| Line item | 2025 |
|---|---|
| Net income | -$13.65M |
| Depreciation | — |
| Change in working capital | — |
| Operating cash flow | — |
| Capital expenditure | — |
| Investing cash flow | — |
| Dividends paid | — |
| Buybacks | — |
| Financing cash flow | — |
| Net change in cash | — |
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | -0.68 | 1 | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target$10.00
High target$10.00
Low target$10.00
Implied upside365.12%
Analyst count1
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders14.04%
Held by institutions25.19%
Institutions holding9
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
727.44K
Total on file
Moving averages & technicals
SMA 10
1.99
+7.77% from price
SMA 20
1.95
+7.78% from price
SMA 50
2.90
-27.58% from price
SMA 100
2.69
-20.17% from price
SMA 200
—
—
EMA 12
2.04
+5.64% from price
EMA 26
2.17
-0.99% from price
EMA 50
2.43
-11.57% from price
RSI (14)
47.8
Neutral
MACD (12,26,9)
-0.14
Hist 0.08
ATR (14)
0.17
8.21% of price
Realised vol 30D
133.3%
Annualised
Bollinger upper
2.20
20, 2σ
Bollinger lower
1.69
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Risk profile
Beta vs SPY
9.09
More volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
133.3%
Annualised
Market vol 1Y
13.2%
SPY, annualised
Max drawdown 1Y
-83.4%
Peak to trough
Max drawdown 5Y
-83.4%
Peak to trough
ATR 14
0.17
8.21% of price
Beta (reported)
—
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Regentis Biomaterials (RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks
NewMediaWire · 5d ago
Regentis Biomaterials (RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market
NewMediaWire · 8d ago
Regentis Biomaterials (RGNT) Advances Regenerative Solution for Major Unmet Need in Cartilage Repair
NewMediaWire · 19d ago
Regentis Biomaterials (RGNT) Targets $3B Cartilage Repair Market with Cell-Free Gelrin C
NewMediaWire · 23d ago
Regentis Biomaterials (RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3B Cartilage Repair Market
NewMediaWire · 26d ago
Regentis Biomaterials Obtains Japanese Patent Allowance for Cartilage Repair Treatment
MT Newswires · 33d ago
Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology
ACCESS Newswire · 33d ago
Regentis Biomaterials (RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process
NewMediaWire · 37d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.